Verastem, Inc. (NASDAQ:VSTM) today announced four poster presentations
at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets
and Cancer Therapeutics being held November 5-9, 2015 in Boston,
Massachusetts.
The details for the poster presentations at AACR-NCI-EORTC are as
follows:
Title: FAK/PYK2 Inhibitors Defactinib and VS-4718 Enhance Immune
Checkpoint Inhibitor Efficacy
Date and time: Friday,
November 6 from 12:15 – 3:15 pm
Location: Exhibit Hall C-D
Session
info: Tumor Immunology Targets
Abstract ID: A191
Title: Focal Adhesion Kinase Inhibition Enables Efficacy of
Checkpoint Immunotherapy in Pancreatic Cancer
Date and time:
Saturday, November 7 from 12:30 – 3:30 pm
Location: Exhibit
Hall C-D
Session info: Tumor Microenvironment
Abstract
ID: B197
Title: FAK Inhibition Induces T Cell-mediated Tumor Regression: A
Novel Role for Nuclear FAK in Controlling Tregs via Transcription of
Cytokine Networks
Date and time: Friday November 6, 2015
12:15 PM - 3:15 PM
Location: Exhibit Hall C-D
Session
info: Tumor Immunology Targets
Abstract ID: A189
Title: FAK Inhibition Targets Cancer Stem Cells
Date and
time: Sunday November 8, 2015 12:30 PM - 3:30 PM
Location:
Exhibit Hall C-D
Session info: Cancer Stem Cells
Abstract
ID: C29
About VS-6063
VS-6063 (defactinib) is an orally available compound designed to target
cancer stem cells through the potent inhibition of focal adhesion kinase
(FAK). Cancer stem cells are an underlying cause of tumor resistance to
chemotherapy, recurrence and ultimate disease progression. Research has
demonstrated that FAK activity is critical for the growth and survival
of cancer stem cells. VS-6063 is currently being studied in the “Window
of Opportunity” study in patients with mesothelioma prior to surgery, a
Phase 1/1b study in combination with paclitaxel in patients with ovarian
cancer, a trial in patients with KRAS-mutated non-small cell lung cancer
and a trial evaluating the combination of VS-6063 and VS-5584 in
patients with relapsed mesothelioma.
About VS-4718
VS-4718 is an orally available compound designed to target cancer stem
cells through the potent inhibition of focal adhesion kinase (FAK).
VS-4718 is currently being studied in a Phase 1 dose escalation study in
patients with advanced cancers.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to
treat cancer by the targeted killing of cancer stem cells. Cancer stem
cells are an underlying cause of tumor recurrence and metastasis.
Verastem is developing small molecule inhibitors of signaling pathways
that are critical to cancer stem cell survival and proliferation: FAK
and PI3K/mTOR. For more information, please visit www.verastem.com.
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development and activity of the Company’s product
candidates, VS-6063 and VS-4718, and the Company’s FAK program
generally, and the potential for combination of FAK inhibitors with
immuno-oncology agents. The words “anticipate,” “appear,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,”
“target,” “potential,” “will,” “would,” “could,” “should,” “continue,”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. Each forward-looking statement is subject to risks
and uncertainties that could cause actual results to differ materially
from those expressed or implied in such statement. Applicable risks and
uncertainties include the risks that the preclinical testing of the
Company’s product candidates and preliminary or interim data from
clinical trials may not be predictive of the results or success of
ongoing or later clinical trials, that data may not be available when we
expect it to be, that enrollment of clinical trials may take longer than
expected, that our product candidates will cause unexpected safety
events, that the Company will be unable to successfully initiate or
complete the clinical development of its product candidates, that the
development of the Company’s product candidates will take longer or cost
more than planned, and that the Company’s product candidates will not
receive regulatory approval or become commercially successful products.
Other risks and uncertainties include those identified under the heading
“Risk Factors” in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2014 and in any subsequent SEC filings. The
forward-looking statements contained in this press release reflect the
Company’s current views with respect to future events, and the Company
does not undertake and specifically disclaims any obligation to update
any forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151027005940/en/
Copyright Business Wire 2015